TREATMENT READING

Agnostic Cancer Therapies (PDQ®)

Choose a source section by treatment, subtype or setting. Patient and professional reading are labelled separately.

Selected text from the National Cancer Institute, with original links and dates. This Triangle reading page is not an NCI PDQ summary. Source topics may be broader than an individual diagnosis.

25 studies cited in this topic · see design and results →

Find a treatment or settingReading level

21 sections · Source headings, not a ranked treatment list

Health professional

Introduction

Health professional

Microsatellite Instability–High or Mismatch Repair–Deficient Solid Tumors

Health professional · Microsatellite Instability–High or Mismatch Repair–Deficient Solid Tumors

Pembrolizumab

Health professional · Microsatellite Instability–High or Mismatch Repair–Deficient Solid Tumors

Dostarlimab

Health professional

Tumor Mutational Burden–High (≥10 Mutations/Megabase) Solid Tumors

Health professional · Tumor Mutational Burden–High (≥10 Mutations/Megabase) Solid Tumors

Pembrolizumab

Health professional

NTRK Gene Fusion–Positive Solid Tumors

Health professional · NTRK Gene Fusion–Positive Solid Tumors

Entrectinib

Health professional · NTRK Gene Fusion–Positive Solid Tumors

Larotrectinib

Health professional · NTRK Gene Fusion–Positive Solid Tumors

Repotrectinib

Health professional

BRAF V600E Variant–Positive Solid Tumors

Health professional · BRAF V600E Variant–Positive Solid Tumors

Dabrafenib in Combination With Trametinib

Health professional

RET Gene Fusion–Positive Solid Tumors

Health professional · RET Gene Fusion–Positive Solid Tumors

Selpercatinib

Health professional

FGFR1-Rearranged Myeloid/Lymphoid Neoplasms

Health professional · FGFR1-Rearranged Myeloid/Lymphoid Neoplasms

Pemigatinib

Health professional

HER2–Expressing Solid Tumors

Health professional · HER2–Expressing Solid Tumors

Trastuzumab Deruxtecan (T-DXd)

Health professional

Potential Emerging Agnostic Targets Not Yet Approved by the U.S. Food and Drug Administration

Health professional · Potential Emerging Agnostic Targets Not Yet Approved by the U.S. Food and Drug Administration

Tumor Mutational Burden–High (TMB-H) (≥16 Mutations/Megabase [mut/Mb]) Solid Tumors

Health professional · Potential Emerging Agnostic Targets Not Yet Approved by the U.S. Food and Drug Administration / Tumor Mutational Burden–High (TMB-H) (≥16 Mutations/Megabase [mut/Mb]) Solid Tumors

Atezolizumab

Preserved source evidence · Independent clinical review pending · Not medical advice